Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1997 2
1999 1
2000 1
2002 1
2005 3
2006 2
2007 2
2008 3
2009 2
2010 2
2011 1
2012 7
2013 10
2014 13
2015 8
2016 5
2017 15
2018 9
2019 10
2020 9
2021 10
2022 8
2023 6
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

120 results

Results by year

Filters applied: . Clear all
Page 1
Pleomorphic Onychomatricoma: A Mimicker of Malignancy.
Perrin C, Ambrosetti D. Perrin C, et al. Among authors: ambrosetti d. Acta Derm Venereol. 2022 Jan 5;102:adv00628. doi: 10.2340/actadv.v101.546. Acta Derm Venereol. 2022. PMID: 34694416 Free PMC article.
Évaluation du profil plasmatique des microARNs, comme marqueur diagnostic du cancer localisé de la prostate avec confirmation des analyses par prélèvement tissulaire sur spécimens après prostatectomie radicale élargie.
Tibi B, Durand M, Rouscoff Y, Lee J, Mauduit C, Ambrosetti D, Mahate Z, Wijeratne V, Severac F, Carpentier X, Marsaud A, Mentine N, Quintens H, Amiel J, Chevallier D, Benahmed M. Tibi B, et al. Among authors: ambrosetti d. Prog Urol. 2014 Nov;24(13):787-8. doi: 10.1016/j.purol.2014.08.014. Epub 2014 Oct 30. Prog Urol. 2014. PMID: 26461539 French. No abstract available.
Targeting of c-MET and AXL by cabozantinib is a potential therapeutic strategy for patients with head and neck cell carcinoma.
Hagege A, Saada-Bouzid E, Ambrosetti D, Rastoin O, Boyer J, He X, Rousset J, Montemagno C, Doyen J, Pedeutour F, Parola J, Bourget I, Luciano F, Bozec A, Cao Y, Pagès G, Dufies M. Hagege A, et al. Among authors: ambrosetti d. Cell Rep Med. 2022 Sep 20;3(9):100659. doi: 10.1016/j.xcrm.2022.100659. Cell Rep Med. 2022. PMID: 36130479 Free PMC article.
The Polo-like kinase 1 inhibitor onvansertib represents a relevant treatment for head and neck squamous cell carcinoma resistant to cisplatin and radiotherapy.
Hagege A, Ambrosetti D, Boyer J, Bozec A, Doyen J, Chamorey E, He X, Bourget I, Rousset J, Saada E, Rastoin O, Parola J, Luciano F, Cao Y, Pagès G, Dufies M. Hagege A, et al. Among authors: ambrosetti d. Theranostics. 2021 Sep 21;11(19):9571-9586. doi: 10.7150/thno.61711. eCollection 2021. Theranostics. 2021. PMID: 34646387 Free PMC article.
[An unusual furuncle].
Cardot-Leccia N, Ambrosetti D, Haudebourg J, Baylet-Vincent F, Saint-Paul MC, Michiels JF, Burel-Vandenbos F. Cardot-Leccia N, et al. Among authors: ambrosetti d. Presse Med. 2008 Sep;37(9):1342-5. doi: 10.1016/j.lpm.2008.06.001. Epub 2008 Jul 17. Presse Med. 2008. PMID: 18644322 French. No abstract available.
The long non-coding RNA TAZ-AS202 promotes lung cancer progression via regulation of the E2F1 transcription factor and activation of Ephrin signaling.
Gobbi G, Grieco A, Torricelli F, Sauta E, Santandrea G, Zanetti E, Fantini V, Reggiani F, Strocchi S, Paci M, Vohra M, Saladi SV, Ambrosetti DC, Ciarrocchi A, Sancisi V. Gobbi G, et al. Among authors: ambrosetti dc. Cell Death Dis. 2023 Nov 18;14(11):752. doi: 10.1038/s41419-023-06277-y. Cell Death Dis. 2023. PMID: 37980331 Free PMC article.
Mechanisms underlying differential responses to FGF signaling.
Dailey L, Ambrosetti D, Mansukhani A, Basilico C. Dailey L, et al. Among authors: ambrosetti d. Cytokine Growth Factor Rev. 2005 Apr;16(2):233-47. doi: 10.1016/j.cytogfr.2005.01.007. Epub 2005 Mar 5. Cytokine Growth Factor Rev. 2005. PMID: 15863038 Review.
120 results